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2679range of 11.8% to 25.6%, and 30-day RSRR was 20.9%
(20.2% to 22.1%) with a range of 17.1% to 24.4%.
The top 7 principal diagnoses for these readmissions
were heart failure (4.8% of all readmissions), post-
operative complications such as shock, hematoma,
wound dehiscence, and infection (1.4%), arrhyth-
mias (1.1%), sepsis (0.9%), pneumonia (0.8%),
gastrointestinal bleed (0.6%), and mechanical device
complications (0.5%). Adjusting for patient charac-
teristics, the odds of each adverse outcome for a pa-
tient treated at a hospital 1 SD above the national
average relative to that of a patient treated at a hos-
pital 1 SD below the national average was statistically
signiﬁcant (Figure 1).
Since the Food and Drug Administration approval
of TAVR in November 2011, there has been rapid
expansion in the number of hospitals performing
TAVR. Our results show marked variation in hospital
performance with TAVR, with an IQR of 1.8% for 30-
day RSMR. For perspective, the IQR for 30-day
RSMR for isolated coronary artery bypass grafting, a
commonly performed invasive cardiac procedure,
is 1% (4).
We found that for an individual patient, the
between-hospital variation translates to a >2-fold
higher risk of dying within 30 days for a patient un-
dergoing TAVR at a hospital 1 SD above the national
average compared with undergoing TAVR at a hos-
pital 1 SD below. The between-hospital variation was
lower for 1-year mortality and 30-day readmission,
but remained substantial. Some of this between-
hospital variation can be attributed to clinical fac-
tors insufﬁciently captured by our adjustment model,
but hospital and system factors are likely also
important drivers of this variation. In addition, TAVR
volume and duration of center experience were
not assessed and could inﬂuence outcomes. As the
importance of hospital and system factors was not
investigated in this paper henceforth, the conclu-
sions of this paper reﬂect the authors’ opinion.
This study serves as an important benchmark
for quality measurement and future performance
improvement efforts for TAVR. Moving forward, as
more centers and operators begin performing TAVR,
and existing centers and operators become more
proﬁcient, it will be important to continue to monitor
the extent of hospital variation to ensure the delivery
of optimal outcomes for patients.Karthik Murugiah, MD
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2015.Effect of Vitamin D
Supplementation on
Aortic Stiffness and
Arterial Hemodynamics
in People With
Osteoarthritis and
Vitamin D DeﬁciencyIncreased aortic stiffness (aPWV), peripheral blood
pressure (pBP), and central hemodynamic parameters
independently predict cardiovascular events and all-
cause mortality (1,2). Moreover, BP variability (BPV)
TABLE 1 Changes in
and Overall VVV BPV
aPWV, m/s
Peripheral SBP, mm Hg
Peripheral DBP, mm Hg
MAP, mm Hg
Peripheral PP, mm Hg
Central SBP, mm Hg
AP, mm Hg
Central PP, mm Hg
AIx@75
Visit-to-visit BPV†
Peripheral systolic B
Peripheral diastolic B
Mean aortic pressure
Central systolic BP
Values are beta coefﬁcient
action between group and
participants who complete
AIx@75 ¼ augmentation
BP ¼ blood pressure; BPV
pressure; PP ¼ pulse press
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2680has been shown to be an independent predictor of
cardiovascular risk (3). Data from intervention studies
assessing the effects of vitamin D on aPWV and BP
indices are sparse and inconclusive. There are no
vitamin D intervention studies targeting visit-to-visit
(VVV) BPV.
People with osteoarthritis (OA) represent a pop-
ulation enriched with vascular risk factors that may
be amenable to beneﬁt with treatment from vitamin D
supplementation. Here, we present ﬁndings from
a substudy of a clinical trial investigating the
effect of vitamin D supplementation on musculoskel-
etal outcomes among older people with vitamin D
deﬁciency and OA (principal trial study design pre-
viously published) (4). The aim of this substudy
was to determine the effects of vitamin D supplemen-
tation on aPWV, pBP, central blood pressure (cBP),
and VVV indices.
Participants were randomized to receive interven-
tion (monthly capsule of 50,000 IU [1.25 mg] cho-
lecalciferol) or identical inert placebo. Duplicate
measures of supine aPWV (carotid-to-femoral tonom-
etry), pBP (automatic oscillometry), and cBP (radial
arterial tonometry) were recorded at baseline,
and 6 and 12 months. VVV was quantiﬁed using
the coefﬁcient of variation ([standard deviation/
mean BP]100). Between-group differences in the
change in outcomes were assessed across the 3 time
points using mixed-effect model analysis (veriﬁedAortic Stiffness, Peripheral and Central Hemodynamic Parameters,
by Study Arm
Intervention
(n ¼ 118)
Placebo
(n ¼ 123) p Value*
0.26 (0.62 to 0.10)† 0.06 (0.30 to 0.43) 0.22
3.00 (5.60 to 0.40) 2.94 (5.59 to 0.30) 0.98
1.47 (3.00 to 0.06) 0.53 (2.09 to 1.03) 0.40
2.08 (3.93 to 0.24) 1.48 (3.36 to 0.39) 0.66
2.48 (4.35 to 0.61) 0.95 (2.76 to 0.85) 0.25
2.77 (5.42 to 0.11) 2.90 (5.59 to 0.22) 0.94
0.84 (1.86 to 0.17) 0.16 (1.17 to 0.86) 0.35
2.10 (4.03 to 0.18) 0.93 (2.81 to 0.95) 0.40
0.54 (1.75 to 0.68) 0.77 (0.45 to 1.99) 0.14
P 6.90  4.49 6.07  4.67 0.21
P 7.16  4.14 6.52  4.08 0.28
6.64  3.93 5.84  4.20 0.17
7.21  4.39 6.91  5.34 0.67
s (95% conﬁdence intervals) or coefﬁcient of variation  SD. *p Value for the inter-
time (mixed-effects linear regression). †BPV indices were calculated among those
d all 3 visits, and represent the absolute values over the 12-month follow-up period.
index adjusted for heart rate; AP ¼ augmentation pressure; aPWV ¼ aortic stiffness;
¼ blood pressure variability; DBP ¼ diastolic blood pressure; MAP ¼ mean arterial
ure; SBP ¼ systolic blood pressure; VVV ¼ visit-to-visit.with generalized estimating equations) with
maximum likelihood estimations for missing data.
Changes in aPWV were also estimated after adjusting
for changes in mean arterial pressure (MAP). The
sample size allowed for a clinically signiﬁcant differ-
ence of at least 0.5 m/s for aPWV and 4.5 mm Hg for
peripheral and central systolic BP.
Participants (age 63  7 years, 49% female) with
vitamin D deﬁciency (43.12  12.24 nmol/l) and knee
OA were randomly assigned to intervention (n ¼ 118)
or placebo (n ¼ 123). Baseline vitamin D, age, sex, BP
indices, and aPWV were similar between groups.
Fifty-one percent of intervention participants and
48% of placebo participants self-reported hyperten-
sion. Vitamin D increased with intervention com-
pared with placebo (45.10 [95% conﬁdence interval
(CI): 40.20 to 49.93] nmol/l vs. 7.99 [95% CI: 4.32 to
11.66] nmol/l; p < 0.001).
There was no signiﬁcant between-group difference
in the change in aPWV (Table 1). The difference
attenuated after adjustment for changes in MAP
(0.10 [95% CI: 0.47 to 0.26] m/s vs. 0.05 [95% CI:
0.33 to 0.42] m/s; p ¼ 0.56). Post-hoc analysis
among participants with high baseline aPWV (>10m/s;
intervention n ¼ 34 vs. placebo n ¼ 33) showed a near
signiﬁcant intervention effect (intervention:1.77m/s
[95% CI: 2.57 to 0.97] vs. placebo: 0.72 m/s
[95% CI: 1.50 to 0.07]; p ¼ 0.065). However, this
attenuated after adjustment for changes in MAP
(p ¼ 0.14). There were no signiﬁcant between-group
differences for changes in any of the pBP, cBP, or
VVV indices (Table 1).
This is the longest vitamin D intervention trial, to
our knowledge, assessing the effect on aPWV, and
the results are concordant with previous studies of
considerably shorter duration. Importantly, when
accounting for the BP effect on aPWV by adjusting for
changes in MAP, the treatment effect decreased
from 0.26 to 0.10 m/s. It is also the longest trial to
test the effects on cBP indices, and the results conﬁrm
negative effects in smaller studies of select patient
populations. Our ﬁndings also add novel information
on VVV and conﬁrm recent work showing no effect of
vitamin D on pBP.
Despite being the longest study to date, limitations
include a relatively short follow-up and lack of data
on cardiovascular events, as well as mineral meta-
bolism markers that could have affected results
(i.e., calcium). Lastly, ﬁndings may not be generaliz-
able to people with severe vitamin D deﬁciency.
In conclusion, we found no effect of vitamin D
supplementation on aPWV, BP, or VVV among
older people with vitamin D deﬁciency and OA.
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2681Despite a plethora of observational data supporting
a relationship between vitamin D and cardiovas-
cular health via pathways involving BP and large
artery stiffness, evidence from our high-quality
clinical trial and other existing trials do not support
the use of vitamin D supplementation as an inter-
vention to improve these endpoints. Previously
documented associations between vitamin D, aPWV,
and BP are likely to be epiphenomena rather
than causative, and vitamin D supplementation for
these aspects of cardiovascular health cannot be
recommended.Panagiota Veloudi, MRes
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NephropathyWe congratulate Bohm et al. (1) for their interesting
study regarding the effects of warfarin or dabigatran
etexilate (DE) on renal function in the patientswith atrial ﬁbrillation (AF) receiving oral anti-
coagulation, showing a decline in renal function
that was greater in those taking warfarin compared
with DE, which was ampliﬁed by diabetes and pre-
vious vitamin K antagonist use. The authors pro-
pose this adverse renal outcome may be due to
inhibition by warfarin of vitamin K–dependent ma-
trix gamma-carboxyglutamic acid (Gla/MPG) and
resulting in renal vascular calciﬁcation and arterial
damage.
Recent data showed that excessive anticoagulation
with warfarin can result in acute kidney injury (AKI)
by causing glomerular hemorrhage and renal tubular
obstruction by red blood cell (RBC) casts in some
patients, especially in those with chronic kidney
disease (CKD), which was described as warfarin-
related nephropathy (WRN) (2). Brodsky et al. (3)
was the ﬁrst to describe this entity through kidney
biopsy in a subset of patients with warfarin overdose,
hematuria, and AKI, and each biopsy specimen
demonstrated evidence of acute tubular injury,
glomerular hemorrhage, and renal tubular obstruc-
tion by RBC casts. Actually, oxidative stress damage
to tubules by an RBC cast, even though the RBC cast
did not obstruct the tubule, could lead to WRN. Other
important mechanisms, including atheroembolism,
interstitial nephritis, apoptosis of glomerular endo-
thelial cells, and direct effects of warfarin on the
glomerulus, may also contribute to the development
of WRN.
A recent case report (4) also described an
anticoagulant-related AKI in a patient who was re-
ceiving the thrombin inhibitor dabigatran. Further-
more, Ryan et al. (5) investigate the effects of
dabigatran on kidney function in an animal model of
CKD, demonstrating that dabigatran resulted in
a dose-dependent increase in serum creatinine and
hematuria in both control and 5/6 nephrectomy rats.
Morphologically, the ﬁndings in 5/6 nephrectomy
rats treated with dabigatran were similar to those
found in animals with WRN, involving RBC tubular
casts and acute tubular injury. Unexpectedly, in
comparison with WRN, in which kidney injury was
seen only in 5/6 nephrectomy rats, the effects of
dabigatran were highlighted in control rats as
well. These ﬁndings suggest that the risk to the kid-
ney by dabigatran may be greater than that by
warfarin in patients with normal renal function,
which should be taken into account in clinical
practice, indicating that regular monitoring of
kidney function may be necessary in patients re-
ceiving oral anticoagulation therapy including
warfarin or dabigatran.
